[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-grade-b-cell-lymphoma-nos\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-grade-b-cell-lymphoma-nos":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100642651",false,"NCT07638982","Axatilimab + CAR-T for High-Risk Lymphoma","An Open-label, Phase I Trial, With an Expansion Cohort: Macrophage Conditioning to Synergize With CAR-T in High-risk Lymphoma (MAC-SHIFT)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed large B-cell lymphoma\n* Presence of one or more high-risk features\n* Eligible to receive CAR-T according to the FDA label\n* Measurable disease by CT or PET\n* Adequate organ function unless related to lymphoma involvement:\n* Pulse oximetry ≥ 92% on room air\n* Ejection Fraction ≥ 40%\n* ALT\u002FAST \\\u003C 5x ULN\n* Bilirubin \\\u003C 3 x ULN\n* Calculated or measured creatinine Clearance ≥ 30 mL\u002Fmin\n\nExclusion Criteria:\n\n* KPS \\\u003C60\n* Second malignancy with a high metastatic potential within 3 years\n* Active CNS involvement. Treated CNS disease is allowed\n* Active HBV or HCV infection.\n* Active uncontrolled infections\n* Known HIV positive status\n* Allogeneic transplant within 100 days of enrollment\n* Active acute or chronic graft versus host disease\n* History of acute or chronic pancreatitis\n* History of myositis","ALL","8 Years",{"count":18,"type":19},29,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","Axatilimab + CAR-T in High-Risk Lymphoma",[25,26,27,28,29,30],"Diffuse Large B Cell Lymphoma (DLBCL)","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","High-grade B-cell Lymphoma (HGBCL)","High-Grade B-Cell Lymphoma, Nos","PMBCL","Follicular Grade 3 Lymphoma","NOT_YET_RECRUITING","2026-06-05",{"date":34,"type":35},"2026-06-10","ACTUAL",{"date":37,"type":19},"2026-10-31",{"date":39,"type":19},"2029-12-31",{"name":41,"class":42},"Northside Hospital, Inc.","OTHER",""]